Cargando…

Immune-Checkpoint Inhibitors in B-Cell Lymphoma

SIMPLE SUMMARY: Immune-based treatment strategies, which include immune checkpoint inhibition, have recently become a new frontier for the treatment of B-cell-derived lymphoma. Whereas checkpoint inhibition has given oncologists and patients hope in specific lymphoma subtypes like Hodgkin lymphoma,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armengol, Marc, Santos, Juliana Carvalho, Fernández-Serrano, Miranda, Profitós-Pelejà, Núria, Ribeiro, Marcelo Lima, Roué, Gaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827333/ https://www.ncbi.nlm.nih.gov/pubmed/33430146 http://dx.doi.org/10.3390/cancers13020214

Ejemplares similares

Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
por: Santos, Juliana Carvalho, et al.
Publicado: (2022)

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022)

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

RHOA Therapeutic Targeting in Hematological Cancers
por: Santos, Juliana Carvalho, et al.
Publicado: (2023)

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2021)

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
por: Ribeiro, Marcelo L., et al.
Publicado: (2019)

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2022)

Epigenetic targets in B- and T-cell lymphomas: latest developments
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2021)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2022)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
por: Quinet, Grégoire, et al.
Publicado: (2022)

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
por: Reyes-Garau, Diana, et al.
Publicado: (2019)

Histone Modifications and Their Targeting in Lymphoid Malignancies
por: Fernández-Serrano, Miranda, et al.
Publicado: (2021)

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
por: Duke, Taylor C., et al.
Publicado: (2020)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
por: Lin, Ningjing, et al.
Publicado: (2020)

T-cell lymphoma secondary to checkpoint inhibitor therapy
por: Anand, Kartik, et al.
Publicado: (2020)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors
por: Scheuerpflug, Anne, et al.
Publicado: (2020)

Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
por: Wirsching, Hans-Georg, et al.
Publicado: (2021)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
por: Nijland, Marcel, et al.
Publicado: (2017)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
por: Joshi, Maansi, et al.
Publicado: (2020)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Mechanism of resistance to immune checkpoint inhibitors
por: Pandey, Manu R., et al.
Publicado: (2019)

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas
por: Witte, Hanno Maximilian, et al.
Publicado: (2023)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Epidemiology and prognosis factors in open globe injuries in the Federal District of Brazil
por: Peleja, Marina Berquó, et al.
Publicado: (2022)

Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy: Biomarkers Versus Imaging
por: Vallejo-Camazón, Nuria, et al.
Publicado: (2022)

Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
por: Kuo, Jean R., et al.
Publicado: (2018)

Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Jiménez-Alejandre, Rosa, et al.
Publicado: (2022)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jiapcnl5e286qa0r473btqv4g